目的 觀察貝那普利聯(lián)合阿托伐他汀鈣片治療冠心病的療效。方法 2014年2月到2017年1月選擇在定邊縣人民醫(yī)院診治的冠心病患者165例作為研究對(duì)象，按照納入時(shí)間的先后順序進(jìn)行編號(hào)，查隨機(jī)數(shù)字表分為觀察組83例與對(duì)照組82例，對(duì)照組給予貝那普利治療，觀察組給予阿托伐他汀鈣片聯(lián)合貝那普利治療，都治療觀察3個(gè)月。比較兩組臨床療效，用超聲心動(dòng)儀檢測(cè)兩組左心室舒張末期內(nèi)徑（LVDd）和射血分?jǐn)?shù)（EF），檢測(cè)兩組治療前后三酰甘油（TG）、總膽固醇（TC）、高密度脂蛋白膽固醇（HDL-C）、低密度脂蛋白膽固醇（LDL-C）等血脂指標(biāo)改善情況。結(jié)果 治療后觀察組的總有效率為98.8%，對(duì)照組為89.0%，觀察組的總有效率明顯高于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后觀察組與對(duì)照組的LVDd值都明顯降低，而EF都明顯升高，與同組治療前對(duì)比差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后觀察組的LVDd更低、EF值更高，與對(duì)照組對(duì)比差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組與對(duì)照組治療后的TG、TC與LDL-C值都明顯低于治療前，而HDL-C值明顯高于治療前，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后觀察組的TG、TC與LDL-C值低于對(duì)照組、HDL-C高于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 阿托伐他汀鈣片聯(lián)合貝那普利治療冠心病用能發(fā)揮更好的降脂效應(yīng)，能促進(jìn)心功能的改善，提高治療效果，有很好的應(yīng)用價(jià)值。

Objective: To observe the curative effects of benazepril combined with atorvastatin in the treatment of coronary heart disease. Methods: From February 2014 to January 2017, 165 patients with coronary heart disease in our hospital were selected as the research object, all the patients were randomly divided into observation group of 83 cases and control group of 82 casesaccorded to the sequence of time in number. The control group was given the benazepril treatment, the observation group was given benazepril combined with atorvastatin treatment for 3 months. Results: After treatment, the total effective rate of the observation group was 98.8%, and that of the control group was 89%. The total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the LVDd values observation group and the control group were significantly decreased, while the EF values were increased significantly, compared with before treatment were significantly different (P<0.05); the LVDd, EF values in the observation group after treatment compared with the control group were statistically significantly difference (P<0.05). The TG, TC and LDL-Cobservation group and the control group after treatment were significantly lower than those before treatment, while the HDL-C value weresignificantly higher than before treatment (P<0.05), and the TC, TC, HDL-C and LDL-C values in the the observation group after treatment compared to the control group were statistically significantly difference (P<0.05). Conclusion: The Benazepril combined with atorvastatin in the treatment of coronary heart disease can play a better lipid-lowering effect, it can promote the improvement of heart function and improve the therapeutic effect, so it has good application values.